Ignite Creation Date:
2025-12-25 @ 2:48 AM
Ignite Modification Date:
2025-12-26 @ 1:29 AM
Study NCT ID:
NCT06188533
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-12-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital
Sponsor:
Assiut University
Organization:
Study Overview
Official Title:
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Urinary Activin A as amarker for assessement of acute kidney injury severity in patient admitted at Assuit University Hospital
Detailed Description:
Acute kidney injury has been ahealth problem all over the world , It's prevelance in developing and developed countries is increasing due to pre renal , renal , post renal causes .
Estimates of AKI prevalence range from \<1% to 66%. These variations can be explained by not only population differences but also inconsistent use of standardized AKI classification criteria. The aetiology and incidence of AKI also differ between high-income and low-to-middle-income countries.(1)
* It can be presented in different stages according to AKIN classification (stage l (Increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to \>150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (\<0.5 ml/kg/h for \>6 h ))
* stage ll (Increase to \>200% to 300% (\>2 fold to 3 fold) from baseline) , and urine output (\<0.5 ml/kg/h for \>12 h ))
* stage lll(Increase in serum creatinine to \>300% (\>3 fold) from baseline, or serum creatinine \>4.0mg/dl (\>354μmol/l) with acute increase of atleast 0.5mg/dl ) Urine output(\<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2)
* In ischemic kidney, there is acytokine belong to the transforming growth factor (TGF)-B ( Activin A) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3)
* level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4)
* so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4)
Estimates of AKI prevalence range from \<1% to 66%. These variations can be explained by not only population differences but also inconsistent use of standardized AKI classification criteria. The aetiology and incidence of AKI also differ between high-income and low-to-middle-income countries.(1)
* It can be presented in different stages according to AKIN classification (stage l (Increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to \>150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (\<0.5 ml/kg/h for \>6 h ))
* stage ll (Increase to \>200% to 300% (\>2 fold to 3 fold) from baseline) , and urine output (\<0.5 ml/kg/h for \>12 h ))
* stage lll(Increase in serum creatinine to \>300% (\>3 fold) from baseline, or serum creatinine \>4.0mg/dl (\>354μmol/l) with acute increase of atleast 0.5mg/dl ) Urine output(\<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2)
* In ischemic kidney, there is acytokine belong to the transforming growth factor (TGF)-B ( Activin A) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3)
* level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4)
* so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4)
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: